L. Fehrenbacher

2.2k total citations · 1 hit paper
33 papers, 1.7k citations indexed

About

L. Fehrenbacher is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, L. Fehrenbacher has authored 33 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in L. Fehrenbacher's work include Cancer Treatment and Pharmacology (11 papers), Colorectal Cancer Treatments and Studies (9 papers) and Lung Cancer Research Studies (7 papers). L. Fehrenbacher is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Colorectal Cancer Treatments and Studies (9 papers) and Lung Cancer Research Studies (7 papers). L. Fehrenbacher collaborates with scholars based in United States, Belgium and South Korea. L. Fehrenbacher's co-authors include Alan Sandler, Roy S. Herbst, Róbert Hermann, Diane Prager, David A. Ramies, Mark G. Kris, Xin Li, Vincent A. Miller, Pam Klein and Bruce E. Johnson and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and European Journal of Cancer.

In The Last Decade

L. Fehrenbacher

33 papers receiving 1.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

2005 1.2k citations Roy S. Herbst, Diane Prager et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
L. Fehrenbacher United States	14	1.4k	1.4k	355	229	86	33	1.7k
Jaromı́r Roubec Czechia	9	1.3k 0.9×	1.3k 0.9×	574 1.6×	170 0.7×	38 0.4×	23	1.7k
J. A. Engelman United States	12	834 0.6×	1.0k 0.7×	511 1.4×	257 1.1×	55 0.6×	24	1.3k
Akito Hata Japan	25	1.1k 0.7×	1.4k 1.0×	320 0.9×	325 1.4×	54 0.6×	117	1.7k
Georgiana Kuhlmann United States	5	753 0.5×	920 0.7×	500 1.4×	357 1.6×	59 0.7×	6	1.3k
Dana Ghiorghiu United Kingdom	15	808 0.6×	929 0.7×	497 1.4×	171 0.7×	56 0.7×	36	1.4k
Ri-Qiang Liao China	11	917 0.6×	905 0.7×	314 0.9×	286 1.2×	31 0.4×	36	1.4k
Lorenza Landi Italy	22	1.1k 0.8×	1.0k 0.7×	611 1.7×	423 1.8×	90 1.0×	85	1.8k
Caicun Zhou China	25	1.4k 1.0×	1.3k 0.9×	389 1.1×	360 1.6×	27 0.3×	39	2.0k
V. Alberola Spain	9	1.0k 0.7×	1.1k 0.8×	404 1.1×	212 0.9×	31 0.4×	21	1.5k

Countries citing papers authored by L. Fehrenbacher

Since Specialization

Citations

This map shows the geographic impact of L. Fehrenbacher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Fehrenbacher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Fehrenbacher more than expected).

Fields of papers citing papers by L. Fehrenbacher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Fehrenbacher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Fehrenbacher. The network helps show where L. Fehrenbacher may publish in the future.

Co-authorship network of co-authors of L. Fehrenbacher

This figure shows the co-authorship network connecting the top 25 collaborators of L. Fehrenbacher. A scholar is included among the top collaborators of L. Fehrenbacher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Fehrenbacher. L. Fehrenbacher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Darbinian, Jeanne, et al.. (2019). Benign Papillary Breast Mass Lesions: Favorable Outcomes with Surgical Excision or Imaging Surveillance. Annals of Surgical Oncology. 26(6). 1695–1703. 22 indexed citations

2.

Gadgeel, Shirish M., Rimas V. Lukas, Jerome H. Goldschmidt, et al.. (2018). Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. Lung Cancer. 128. 105–112. 132 indexed citations

3.

Mazières, Julien, C. Lewanski, Shirish M. Gadgeel, et al.. (2018). 136PD_PR 3-year survival and duration of response in randomized phase II study of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC (POPLAR). Journal of Thoracic Oncology. 13(4). S79–S79. 16 indexed citations

4.

Greenlee, Heather, Danika L. Lew, Dawn L. Hershman, et al.. (2018). Phase II Feasibility Study of a Weight Loss Intervention in Female Breast and Colorectal Cancer Survivors (SWOG S1008). Obesity. 26(10). 1539–1549. 5 indexed citations

5.

Fehrenbacher, L., CE Geyer, Priya Rastogi, et al.. (2018). Abstract GS1-02: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC). Cancer Research. 78(4_Supplement). GS1–2. 40 indexed citations

6.

Lewanski, C., Shirish M. Gadgeel, L. Fehrenbacher, et al.. (2017). MA 10.03 3-Year Survival and Duration of Response in Randomized Phase II Study of Atezolizumab vs Docetaxel in 2L/3L NSCLC (POPLAR). Journal of Thoracic Oncology. 12(11). S1840–S1840. 5 indexed citations

7.

Mamounas, E., Hanna Bandos, BC Lembersky, et al.. (2017). Effect of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer after prior adjuvant therapy with an aromatase inhibitor (AI): NRG Oncology/NSABP B-42. The Breast. 32. S25–S26. 2 indexed citations

8.

Schulz, Carsten‐Oliver, Julien Mazières, Johan Vansteenkiste, et al.. (2016). Efficacy, safety and predictive biomarker results from a randomized phase II study comparing atezolizumab vs docetaxel in patients with advanced NSCLC (POPLAR). 39. 104–104. 1 indexed citations

9.

Melisko, Michelle, DA Yardley, Kimberly Blackwell, et al.. (2016). Abstract OT1-03-15: The METRIC trial: A randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients with metastatic gpNMB-overexpressing triple-negative breast cancer (TNBC). Cancer Research. 76(4_Supplement). OT1–3. 2 indexed citations

10.

Rittmeyer, Achim, K Park, Julien Mazières, et al.. (2016). Efficacy, safety and predictive biomarker results from a randomized phase II study comparing atezolizumab vs. docetaxel in patients with advanced NSCLC (POPLAR). Pneumologie. 70(S 01). 1 indexed citations

11.

Vansteenkiste, Johan, L. Fehrenbacher, Alexander I. Spira, et al.. (2015). 14LBA Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR). European Journal of Cancer. 51. S716–S717. 28 indexed citations

12.

Kushi, Lawrence H., et al.. (2010). Effect of early discontinuation and nonadherence to adjuvant hormone therapy on mortality in women with breast cancer.. Journal of Clinical Oncology. 28(15_suppl). 578–578. 2 indexed citations

13.

Fehrenbacher, L., Howard West, Primo N. Lara, et al.. (2009). Phase II Trial of Irinotecan and Carboplatin for Extensive or Relapsed Small-Cell Lung Cancer. Journal of Clinical Oncology. 27(9). 1401–1404. 34 indexed citations

14.

Polikoff, Jonathan, John D. Hainsworth, L. Fehrenbacher, et al.. (2008). Safety of bevacizumab (Bv) therapy in combination with chemotherapy in subjects with non-small cell lung cancer (NSCLC) treated on ATLAS. Journal of Clinical Oncology. 26(15_suppl). 8079–8079. 14 indexed citations

15.

Fehrenbacher, L., et al.. (2008). Chemotherapy for Brain Metastases in Small-Cell Lung Cancer. Clinical Lung Cancer. 9(1). 35–38. 25 indexed citations

16.

Scappaticci, Frank A., L. Fehrenbacher, Thomas H. Cartwright, et al.. (2004). Lack of effect of bevacizumab on wound healing/bleeding complications when given 28–60 days following primary cancer surgery. Journal of Clinical Oncology. 22(14_suppl). 3530–3530. 2 indexed citations

17.

Herbst, Roy S., Diane Prager, Róbert Hermann, et al.. (2004). TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 22(14_suppl). 7011–7011. 40 indexed citations

18.

Fyfe, G., Herbert I. Hurwitz, L. Fehrenbacher, et al.. (2004). Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups. Journal of Clinical Oncology. 22(14_suppl). 3617–3617. 16 indexed citations

19.

Scappaticci, Frank A., L. Fehrenbacher, Thomas H. Cartwright, et al.. (2004). Lack of effect of bevacizumab on wound healing/bleeding complications when given 28–60 days following primary cancer surgery. Journal of Clinical Oncology. 22(14_suppl). 3530–3530. 13 indexed citations

20.

Miller, V. A., Roy S. Herbst, Diane Prager, et al.. (2004). Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE. Journal of Clinical Oncology. 22(14_suppl). 7061–7061. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact